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A synthetic peptide (residues 139153) corresponding to the receptor-binding domain of apolipoprotein E (ApoE) was 
tested for lipoprotein lipase (LPL) inhibitory properties. In systems using both natural and synthetic substrates, inhibition 
of LPL was observed. Using the synthetic substrate, 50% inhibition was observed at 50 PM while high concentrations 
completely inhibited LPL activity. These studies suggest an additional functional role for the receptor-binding domain 
of ApoE - modulation of LPL activity. 
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1. INTRODUCTION 
Triacylglycerol (TG)-rich lipoproteins during 
their lipolysis catalyzed by lipoprotein lipase (LPL) 
become smaller and are either removed by high- 
affinity receptors (ApoE and/or ApoB/E) or con- 
verted to plasma LDL [1,2]. The catalytic rate of 
LPL in this process is governed both by passive 
modulation of TG uptake related to changes in 
plasma TG concentrations and active regulation of 
LPL activity, e.g. apolipoproteins [3]. One 
apolipoprotein, ApoE, has been previously 
reported [4-71 to have an inhibitory effect on LPL 
catalytic activity. Thus, ApoE may play a dual 
signaling role in the clearance of plasma TG-rich 
lipoproteins: one regulating the rate of lipolysis, 
and the other, uptake by high-affinity receptors 
[ 1,2]. Recently, the receptor-binding domain 
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(RBD) of human ApoE has been localized and 
characterized by Mahley et al. [8]. Because of our 
interest in studying ApoE receptor interactions by 
competition experiments, we have prepared the 
synthetic peptide representing the RBD of ApoE 
(residues 139-153). Since ApoE inhibits LPL ac- 
tivity [4-71 we tested RBD for its possible in- 
hibitory potential in an LPL assay system. The 
subject of this paper is to report that the synthetic 
peptide corresponding to the RBD of ApoE 
represents an important domain in the inhibition 
of LPL. 
2. MATERIALS AND METHODS 
2.1. Peptide synthesis 
The RBD synthetic peptide (residues 139-153 of ApoE) was 
synthesized on an Applied Biosystem synthesizer (model 43OA) 
at the Molecular Biology Resource Facility, Oklahoma Univer- 
sity Health Sciences Center. Peptide synthesis was performed 
using the solid-state methodology as first described by Mer- 
rifield [9]. Briefly, the peptide was synthesized on a solid sup- 
port by stepwise addition of N-protected amino acids. At the 
completion of the synthesis, the peptide was cleaved from its 
solid support and permanent side-chain-protecting groups by 
HF [lo]. Synthesized peptides were purified by preparative 
reversed-phase chromatography. Characterization of purified 
peptides included a single peak by analytical reversed-phase 
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high-pressure liquid chromatography and the expected amino 
acid analysis. 
2.2. Lipoprotein iipase 
2.2.1. Preparation of LPL and substrates 
Bovine milk LPL was used in these studies. The purification 
of bovine milk LPL using heparin-Sepharose affinity 
chromatography was performed as described by Posner et al. 
Ull. 
2.2.2. Assay 
The assay of lipoprotein lipase activity was performed with 
lecithin (dioleoylphosphatidylcholine)-emulsified glycerol tri- 
[9,10-3H]oleate as substrate. The molar ratio of lecithin to 
trioleoylglycerol was 1: 10. The 2-fold concentrated substrate 
was prepared as described by Eckel et al. [12]. The assay mix- 
ture contained 1.4 mM trioleoylglycerol, 60 mg/ml of bovine 
serum albumin, 3% human serum as the source of lipase ac- 
tivator, and an appropriate volume of lOO-fold diluted enzyme 
(lo-20 pl). The final volume of the assay mixture was adjusted 
to 100 pl with the addition of 50 mM N&OH-HCI buffer, pH 
8.5. The mixture was shaken on a water bath at 37°C for 1 h. 
The reaction was terminated by adding 3.2 ml chloroform/hep- 
tane/methanol (5 : 4: 5.6, v/v) and 1 ml of 0.2 N NaOH. After 
centrifugation, 1.2 ml of the top layer was mixed with 10 ml In- 
stage1 (Packard) and the radioactivity measured in a Packard 
liquid scintillation counter. One unit of activity is defined as 
1 nmol fatty acid released per h at 37°C. Alternatively, when a 
VLDL substrate was used, the assay mixture was extracted as 
previously described for determination of the first-order rate 
constant (kr) of TG degradation by gas-liquid chromatography 
(131. 
Table 1 
Inhibition of lipoprotein lipase (LPL) by receptor-binding 
domain of ApoE (residues 139-153, M, 1859) 
Substrate ApoE RBD Inhibitiona 
GM) (Q) 
Native VLDLb 2.4 2.8 
23.9 17.8 
113.1 32.9 
Artificial substrate 433 100 
418 99 
87 68 
17 27 
Artificial substrate’ 
Acetic acid 98.2 65.3 
Albumin 195.7 90.4 
DMSO 233.3 97.6 
DMSO 87.7 88 
a Based on control activity 
b Degree of inhibition based on change in first-order rate 
constant (kr) 
’ Different agents used to solubilize synthetic peptide before 
addition to substrate 
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Fig.1. Effect of RBD of ApoE on degradation of VLDL. 
Disappearance curve of TG following degradation of VLDL by 
LPL in the presence of RBD of ApoE [(o) 113 PM] and its 
absence (0). Plots are best-fit exponential curves as described 
by Wang et al. [13]. 
2.2.3. Inhibition assay 
In the inhibition assay, the synthetic peptide of ApoE was 
added to the assay mixture followed by 204 diluted bovine 
milk LPL. Appropriate controls containing the solvent in each 
case were assayed with only the peptide absent. 
3. RESULTS 
The synthetic RBD of ApoE was solubilized in 
several different buffers and tested using both 
native and synthetic substrate systems (table 1). 
The RBD of ApoE could, at higher concentra- 
tions, completely inhibit LPL activity. LPL in- 
hibitory properties were also observed with a 
shorter synthetic peptide (residues 141-153) which 
its N-terminal acetylated. As illustrated 
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Fig.2. Effect of RBD of ApoE on LPL activity. Synthetic 
substrate system used and different concentrations of RBD of 
ApoE (residues 139-153) added. 
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(fig.l), the addition of RBD of ApoE to VLDL 
decreased (33%) the first-order rate constant (kl) 
for the disappearance of VLDL-TG from 0.0348 to 
0.0221 min-‘. In addition, a plot of the inhibition 
of synthetic substrate degradation using dilutions 
of the RBD of ApoE (fig.2) demonstrated that an 
estimated Ki.50 was of the order of 50pM as 
estimated from the concentration of RBD of ApoE 
necessary to achieve 50% inhibition of TG 
degradation. 
4. DISCUSSION 
The synthetic peptide corresponding to the RBD 
of ApoE has striking inhibitory properties in assay 
systems containing either VLDL or a synthetic 
substrate. Differences in inhibition effect of RBD 
of ApoE using the native or synthetic substrate are 
due to compositional variations in the substrates. 
The estimation of a Ki,so of the order of 50 PM 
with the synthetic substrate suggests that this do- 
main may represent a physiologically important 
regulator of plasma TG levels. In conjunction with 
the role of this domain in receptor binding, such an 
observation indicates that the exposure of the RBD 
of ApoE during lipolysis of TG-rich lipoproteins 
could inhibit LPL and thus direct the partially 
degraded TG-rich lipoprotein to high-affinity 
receptor-mediated uptake by the liver. Such a com- 
petitive mechanism could be important in 
regulating plasma TG levels by both modulating 
LPL activity and clearance of TG-rich lipoproteins 
by receptor-mediated uptake. 
A number of studies have reported changes in 
ApoE structural properties in relation to the in 
vitro characteristics of VLDL following perturba- 
tions including lipolysis [ 14,151, proteolysis [ 161, 
size characteristics of VLDL particles [17] and 
ApoE epitope exposure [17,181, and lipid exchange 
[14]. In addition, phospholipids have been shown 
to be necessary for ApoE binding to receptor [19]. 
All of these studies clearly demonstrate that the 
surface properties of VLDL as mediated by the 
conformation of ApoE could alter the in vivo fate 
of TG-rich lipoproteins or their remnants. 
This study provides new information regarding 
the central role played by the RBD of ApoE in 
regulating the conversion and clearance of TG-rich 
252 
lipoproteins mediated by LPL and points to a 
defined polypeptide probe for future studies on the 
interaction of ApoE with LPL. 
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